The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
 
Yong He
No Relationships to Disclose
 
Li Li
No Relationships to Disclose
 
Liyan Jiang
No Relationships to Disclose
 
Yubo Wang
No Relationships to Disclose
 
Yizhuo Zhao
No Relationships to Disclose
 
Xiaoju Zhang
No Relationships to Disclose
 
Guoming Wu
No Relationships to Disclose
 
Xiangdong Zhou
No Relationships to Disclose
 
Jianguo Sun
No Relationships to Disclose
 
Jun Bai
No Relationships to Disclose
 
Biyong Ren
No Relationships to Disclose
 
Kun Tian
No Relationships to Disclose
 
Zhi Xu
No Relationships to Disclose
 
Hualiang Xiao
No Relationships to Disclose
 
Qi Zhou
No Relationships to Disclose
 
Rui Han
No Relationships to Disclose
 
Hengyi Chen
No Relationships to Disclose
 
Haidong Wang
No Relationships to Disclose
 
Zhenzhou Yang
No Relationships to Disclose
 
Chan Gao
Employment - 3D Medicines